

## A list of published papers:

1. Immunogenicity of synthetic oligopeptides corresponding to epitopes of Friend's murine leukemia virus glycoprotein covalently linked to lipopeptides.  
**Ralph Link, T. Böltz et al.**  
Immunobiol. 178; 64.
2. Histopathological Studies on the local reactions induced by complete Freund's Adjuvant (CFA), bacterial Lipopolysaccharide (LPS), and synthetic Lipopeptide (P3C) Conjugates.  
**Frank Wiedemann, Ralph Link et al.**  
Journal of Pathology, Vol. 164:265-271(1991)
3. Immunogenität synthetischer F-MuLV- und HIV-Oligopeptid-Lipopeptid-Konjugate in BALB/c- und STU-Mäusen.  
**W. Bessler, R. Link et al.**  
Abstract, 2. Deutscher AIDS-Kongress, Berlin, FRG.
4. Safety and Tolerability of Peginterferon Alpha-2A (40KD)(PEGASYS) Monotherapy and combination Therapy with Ribavirin (COPEGUS) in Patients with chronic Hepatitis C: Results of a German, Multicenter open-label trial  
**B. Möller, ..Ralph Link et al.**  
Journal of Viral Hepatitis, Volume 14, Number 11, November 2007, pp788-796(9)
5. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy  
**Wulf O. Böcher, ..Ralph Link et al.**  
Liver International 2006;26; 319-325
6. Comparison of a 24-week standard combination therapy with PEG-IFN alfa-2a/Ribavirin with a 12-week monotherapy with PEG-IFN alfa-2a followed by a 12 week standard combination with PEG-IFN alfa-2a/Ribavirin in Hepatitis C infected patients with genotyp 2 or 3.  
**Kallinowski Birgit, ....Link Ralph et al.**  
Presented at the 57 Annual Meeting of the American Ass. for the Study of Liver Diseases 2006 October 27-31; Boston; Massachusetts; USA
7. K-light chain amyloidosis of the liver, a rare cause of liver enzyme elevation  
**J.P. Borde, R.Link, W.B. Offensperger**  
Dtsch Med Wochenschrift 2008;133;116-1120
8. Estimating the Likelihood of Sustained Virological Response in Chronic Hepatitis C (CHC) Therapy  
**Mauss S., Hueppe D., ....Link R. et al.**  
Presented at the 43 Annual Meeting of the European Ass. for the Study of Liver (EASL) 2008 April 23-27; Milan, Italy  
Journal of Viral Hepatitis, 2010 / j.1365-2893
9. Efficacy and Tolerability of Peginterferon alpha-2a or - 2b plus Ribavirin in the Routine Daily Treatment of Chronic Hepatitis C Patients in Germany: The PRACTICE Study  
**Witthoeft T, Hueppe D., ....Link R. et al.**  
Presented at the 43 Annual Meeting of the European Ass. for the Study of Liver (EASL) 2008 April 23-27; Milan, Italy

10. Comparison of the efficacy of peginterferon alfa-2a and -2b plus ribavirin in the treatment of chronic hepatitis C patients in daily routine: results from Practice  
*Witthoeft Thomas, ...Link Ralph et al.*  
AASLD Poster 2010  
EASL-Abstract 2008, Mailand
  
11. Effektivität und Sicherheit von Escitalopram zur Prävention PEG-IFN-alpha assoziierter Depressionen bei Patienten mit chronischer Hepatitis C (CIPPAD-Studie)  
*Schaefer, M.; Sarkar, R.; ...Link, R.: et al.*  
Hepatology 2008;48(4):423A
  
12. Daily consensus interferon versus peg-interferon alfa2b with weight based ribavirin in treatment-naive patients with chronic hepatitis C serotyp-1  
*M. Schuchmann, H.F. Löhr, R. Link, et al.*  
AASLD 2007
  
13. Daily consensus interferon versus peg-interferon alfa2b with weight based or 800 mg ribavirin in treatment-naive patients with chronic hepatitis C genotypes 2 or 3  
*F. Rahman; M. Schuchmann; H. F. Löhr; R. Link; P. Buggisch; et al*  
AASLD 2007
  
14. consensus interferon/ribavirin versus peg-interferon alfa2b/ribavirin in treatment-naive Daily patients with chronic hepatitis C and serotype-2 or -3: Interim results from the PACT-trial  
*W.O. Böcher, M. Fuchs, P. Buggisch, S. Kaiser, R. Link, et al.*  
AASLD 2007
  
15. longterm benefits of sustained virological response (SVR) in patients with chronic hepatitis C (CHC) virus infection: The German „LOTOS STUDY“  
*Reimer. J., ..... Link.R., et al*  
DDW 2011 Chikago; Posternummer 6795
  
16. Kostenevaluation der ärztlichen Leistung einer Behandlung der cHCV mit Peginterferon alfa-2a und Ribavirin als Beitrag zur Qualitätssicherung im Gesundheitswesen.  
*S.Rossol, M.Schuchmann, ... R.Link, et.al.*
  
17. PEG-Interferon-alfa2a/ribavirin - phlebotomy in HCV GT 1patients – final results of the KAPRI trial.  
*Erhardt, B.Möller, ... R.Link, et. al.*
  
18. Pathological glucose tolerance and treated hypertension identify HCV-patients with negative prognostic parameters for SVR.  
*E. Jaeckel, E.Zehnter, T. Lutz, ... R.Link, et.al.*
  
19. Confirmation of high SVR rates after shortening duration of treatment with Peginterferon alfa-2a (PEG) and Ribavirin (RBV) in Chronic Hepatitis C (CHC) Patient with RVR In Real Life.  
*Stefan Mauss, Ralph Link, et.al.*  
eingereicht AASLD San Franzisco 2011
  
20. Pharmaeconomic Evaluation of chronic HCV Treatment with Peginterferon alfa-2a/Ribavirin-real life setting in a large German cohort of 1147 patients.  
*S.Rossol, M.Schuchmann, S.Mauss...R.Link, et.al*  
eingereicht AASLD San Franzisco 2011

21. The role of ferritin as a response marker for antiviral treatment of chronic Hepatitis C patients with Peginterferon alpha-2a (PegIFN) and Ribavirin (RBV).  
*KLass D.M., Zizer E., **Link R.**, ..., et.al.*  
*eingereicht AASLD San Francisco 2011*
  
22. The role of weight loss (WL) as on treatment predictive Factor for SVR in the treatment of chronic Hepatitis C (CHC) patients with Peginterferon alpha-2a (PEG) and Ribavirin.  
*Thomas Witthoef, Klaus Boeker, ..., **Ralph Link**, et.al.*  
*eingereicht AASLD San Francisco 2011*
  
23. Predictive factors for nonresponse in genotype 2/3 infected chronic hepatitis C patients treated with Peginterferon alpha-2a and Ribavirin in real life setting  
*J.Petersen, T. Lutz, **R. Link**, et al.....*  
*EASL 2012 Abstract A-455-0022-00894, Barcelona, Spain*  
*DDW 2012*
  
24. Viral response at week 2 as a predictive factor for RVR in chronic HCV Genotyp 1 Infection treated with Peginterferon-alpha-2a and Ribavirin  
*S. Mauss; T.Lutz; K.Boeker; **R. Link**; et al.....*  
*EASL 2012 Abstract A-455-0022-0084, Barcelona, Spain*  
*DDW 2012*
  
25. Early markers of metabolic syndrome are associated with distinct HCV genotypes, while abnormal glucose tolerance substantially decreases the likelihood of SVR  
*E. Jaeckel, E. Zehnter, T. Lutz, A.Carlebach, **R. Link** et.al.....*  
*EASL 2012 Abstract, Barcelona, Spain*
  
26. Effects of pre-treatment with bezafibrate followed by standard of care in treatment-naive patients with chronic hepatitis C genotyp 1 infection and elevated GGT levels.  
*A.Böhig, V.Weich, .....**Ralph Link**; et al.....*  
*WORDS Abstract 350*
  
27. Starke Assoziation von Markern des metabolischen Syndroms mit HCV Genotyp 1,4,5 und schlechtes Therapieansprechen bei Patienten mit gestörter Glucosetoleranz.  
*E. Jaeckel, E. Zehnter, **R. Link**; et al-*  
*EASL 2012 Abstract*
  
28. Patient Adherence: The influence of non-virological factors in a real world setting  
*T. Witthöft, **R. Link**; et al-*  
*DGVS 2012,*
  
29. Clinical Presentation of Chronic Liver Disease in Germany: Role of Etiology, Age and Gender,  
*A. Tromm, J. Petersen, P. Buggisch, S. Holm, **R. Link**; et al-*  
*DGVS 2012,*
  
30. Factors associated with rapid virological response (RVR) in the treatment of chronic hepatitis C (cHC) with Peginterferon alpha-2a (PEG) and Ribavirin (RBV) in patients with and without opioid substitution treatment (OST)  
*Jens Reimer; Bernd Weber; .. **Ralph Link**; et.al.*  
*Abstract AASLD 2012, Boston, Massachusetts (1420283)*
  
31. Escitalopram for the prevention of peginterferon alpha-2a- and ribavirin-associated depression in HCV-infected patients  
*Martin Schaefer, MD; ...**Ralph Link**, MD; et. al.*  
*Abstract JAMA 10-7938*

32. Epidemiologie, Behandlungsergebnisse und Kosten der Behandlung chronischer HCV-Patienten in Deutschland – Ergebnisse einer großen Multicenter Studie.  
*Rossol S; Stahmeyer J.T.; Bert F; Mauss S; Link R; et al.*  
Konferenz Viszeralmedizin 2013 Abstract A-592-0004-00323
33. Gründe zur Ablehnung einer Hepatitis C Therapie vor dem Hintergrund neuer Therapieoptionen.  
*Mauss S.;Stoehr A.;Schober A.;Holm S.; Beoker K.H.W.; Link R.; et al*  
Z.Gastro 44(8), 797 Abstr. P275 (2006), Kongress Viszeralmedizin 2013 (DGVS)
34. Prädiktive Baseline Faktoren bei Patienten mit Zirrhose für den Therapieerfolg einer dualen Therapie mit Peginterferon alfa-2a (PEG) plus Ribavirin (RBV), was zählt?  
*Hueppe D.; Mauss S.; .....Link R.; Moog G.; et al*  
eingereicht Kongress Viszeralmedizin 2013 (DGVS)
35. Real world efficacy and safety of 28 week-therapy containing boceprevir, peginterferon alpha-2a and ribavirin in treatment-naive patients: first SVR data of German non-interventional PAN Study  
*Peter Buggisch, Andreas Schober;.....Ralph Link....et al*  
AASLD-The Liver Meeting 2013, Washington,DC
36. 24 week treatment of former relapse, HCV genotyp 1 infected patients with telaprevir in combination with peginterferon alpha 2a/ribavirin-experiences under real life conditions  
*Klaus H. Boeker; Ralph Link et al.*  
AASLD-The Liver Meeting 2013, Washington,DC
37. Baseline characteristics and treatment response of HCV genotyp 1 patients with previous null response that are retreated with TVR or BOC triple therapy in real world setting  
*Wolf P.Hofmann, Stefan Mauss;.....Ralph Link;.....et al*  
AASLD-The Liver Meeting 2013, Washington,DC
38. Patient Adherence: the Influence of Non-virological Factors in a Real word Setting  
*Thomas Witthoeft, Ralph Link, et.al.*  
APASL 2013 abstract
39. Quality of Life Profiles in Patients in Contact with the Hepatitis C Virus  
*Reimer J; Hueppe D;.....Link R;....et al.*  
3rd Intern. Symposium on Hepatitis Care in Substance Users (INHSU 2013);Munich
40. Baseline Characteristics and Treatment Response of HCV Genotyp 1 Patients with Previous Null Response That Are Retreated with TVR or BOC Triple Therapy in Real World Setting  
*Hofmann WP;Mauss S; Baumgarten A; Boeker KH; Link R; ..et al.*  
AASLD-The Liver Meeting 2013, Washington,DC, USA
41. Overtreatment of Patients with chronic Hepatitis C (cHC) Genotyp 2/3 with low baseline viral load and RVR: Experiences ia a real world setting  
*B.Heinrich; St. Wiegand; J.Petersen; H.Hinrichsen; Ralph. Link; et al.*  
AASLD-The Liver Meeting 2013, Washington,DC, USA
42. Performance and value of IFN-Lambda 3 and IFN-Lambda 4 Genotyping in Patients with chronic Hepatitis C (cHC) Genotype 2/3 in a real world setting  
*St. Wiegand; B. Heinrich; S.Susser; ...; Ralph. Link;.. et al.*  
AASLD-The Liver Meeting 2013, Washington,DC, USA

43. 24 Week Re-treatment with Telaprevir-Triple Therapy in Patients with HCV-Genotype 1 who had Relapsed after Peginterferon/Ribavirin Treatment.  
*Boeker KH; Link Ralph; et al.*  
AASLD-The Liver Meeting 2013, Washington,DC, USA
44. Safety analysis of Endoscopist-Directed Sedation. A prospective, national multicenter study of 24.441 patients in German outpatient practices  
*Andreas Sieg, Ralph Link in bng-Study-Group, Sebastian Beck; et al.*  
Gastroenterology , in process
45. Smoking does not negatively influence Interferon-based antiviral Therapy in Treatment naive, HCV Genotype 1 infected Patients  
*Tim Zimmermann; Klaus.H.W. Boecker;Andreas Schober; .... Ralph Link;...et al.*  
EASL 2014, Abstract eingereicht
46. Baseline characteristics and treatment efficacy of telaprevir in combination with peginterferon alfa-2a and ribavirin in 253 HCV genotype 1 nonresponder patients in a real-world setting.  
*W.P. Hofmann; S.Mauss;A.Baumgarten;K.H.W. Boecker; R.Link et al.*  
EASL 2014, Abstract London
47. Triple therapy with boceprevir (BOC) under daily conditions: Is it possible to achieve SVR rates comparable to pivotal trials ?  
*Peter Buggisch; Andreas Schober; ....Ralph Link;... et al.*  
EASL 2014, Abstract London
48. Adverse Events and co-medication: a comparison between dual and triple combination therapies in genotype 1 patients with chronic hepatitis C  
*Eckart Schott; Andreas Schober; Ralph Link; et al.*  
EASL 2014, Abstract London
49. Sustained virological response (SVR) in HCV treatment-experienced patients after triple therapy with boceprevir (BOC) plus peginterferon alfa-2a / ribavirin in a real-life setting.  
*Klaus H.W. Boecker; Ralph Link, Axel Baumgarten; et al.*  
EASL 2014, London
50. *Non-virological factors predicting patient adherence during antiviral treatment of genotyp 1/4 infection in real world: role of gender and age*  
*Thomas Witthoeft; Ralph Link; Stefan Christensen; et al.*  
Hepatology, Volume 58, Number 4; AASLD Abstract 2013 in Washington
51. Baseline characteristics and treatment response of HCV genotype 1 patients with previous null response that are retreated with TVR or BOC triple therapy in real world setting  
*Wolf P. Hofmann; Stefan Mauss; Axel Baumgarten; Klaus H. Boecker; Ralph Link; et al.*  
Hepatology, Volume 58, Number 4; AASLD Abstract 2013 in Washington
52. 24 week treatment of former relapse, HCV genotype 1 infected patients with telaprevir in combination with peginterferon alfa 2a/ribavirin – experiences under real life conditions  
*Klaus H. Boecker; Ralph Link; et al*  
Hepatology, Volume 58, Number 4; AASLD Abstract 2013 in Washington
53. Treatment of naive patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: Relevance for the new era of DAA  
*Benjamin Heidrich;Steffen B. Wiegand;...Ralph Link; Uwe Naumann; et al*  
PLOS ONE October 2014 / Volume 9 / Issue 10 / e108751

54. Respiratory Complications in Outpatient Endoscopy with Endoscopist-Directed Sedation.  
*Kilian Friedrich; Sabine G. Scholl;... Ralph Link in bng-Study-Group; Andreas Sieg et al.*  
J. Gastrointestin Liver Dis, September 2014; Vol. 23 No 3.
55. Treatment of Naive Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting;  
Relevance for the New Era of DAA  
*Benjamin Heidrich;Steffen B. Wiegand;...Ralph Link; ,,, Markus Cornberg, et al*  
PLOS ONE October 2014 / Volume 9 / Issue 10 / e108751
56. Treatment of patients with hepatitis C virus (HCV) genotype 3 infection in the era of direct acting antivirals (DAA): Data from the German Hepatitis C-Registry (DHC-R)  
*Markus Cornberg, Peter Buggisch,... Ralph Link,.....et.al*  
The International Liver Congress / EASL 2016
57. Outcomes and costs of treating hepatitis C patients in the era of first generation protease inhibitors-Results from the PAN study.  
*J.T. Stahmeyer, S. Rossol, .....R.Link, Ch. Krauth et.al*

*Stand: 01.04.2016 gez: Dr. Ralph Link*